Popular Option Trade Spurs Japan Bourse to Seek New ETF Listings
Save
Japan's main bourse is seeking to capitalize on the growth of strategies that enhance yield.
Trades such as call overwriting — when investors who own shares sell bullish options to pocket the contracts' premium — have become increasingly popular in Japan, and the Tokyo Stock Exchange now wants to enable listings of actively managed exchange-traded funds with over-the-counter derivatives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
China is betting on a real-world use of AI to challenge U.S. control
SHANGHAI - As the United States and China vie for control over the future of artificial intelligence, Beijing has embarked on an all-out drive to transform the technology from a remote concept to a newfangled reality, with applications on factory floors and in hospitals and government offices. China does not have access to the most advanced chips required to power cutting-edge models due to restrictions from Washington and is still largely playing catch-up with Silicon Valley giants like OpenAI. But experts say Beijing is pursuing an alternative playbook in an attempt to bridge the gap: aggressively pushing for the adoption of AI across the government and private sector. (The Washington Post has a content partnership with OpenAI.) Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. 'In China, there's definitely stronger government support for applications and a clear mandate from the central government to diffuse the technology through society,' said Scott Singer, an expert on China's AI sector at the Carnegie Endowment for International Peace. By contrast, the U.S. has been more focused on developing the most advanced AI models while 'the application layer has been totally ignored,' he said. China's push was on full display in Shanghai at its World Artificial Intelligence Conference, which ran until Tuesday. Themed 'Global Solidarity in the AI Era,' the expo is one part of Beijing's bid to establish itself as a responsible AI leader for the international community. This pitch was bolstered by the presence of international heavyweights like Eric Schmidt, former CEO of Google, and Geoffrey Hinton, a renowned AI researcher often called the 'Godfather of AI.' During the event, Beijing announced an international organization for AI regulation and a 13-point action plan aimed at fostering global cooperation to ensure the technology's beneficial and responsible development. 'China attaches great importance to global AI governance,' Li Qiang, China's premier, said at the opening ceremony on Saturday. It 'is willing to share its AI development experience and technological products to help countries around the world - especially those in the Global South,' he said, according to an official readout. Just last week, President Donald Trump announced a competing plan in a bid to boost American AI competitiveness by reducing regulation and promoting global exports of U.S. AI technology. Washington has moved in recent years to restrict China's access to chips necessary for AI development, in part due to concerns about potential military applications of such models and degrading U.S. tech leadership. The Trump administration's approach to chip policy, however, has been mixed. Earlier this month, the White House reversed a previous ban on specific AI chips made by U.S. tech giant Nvidia being exported to China. This shift occurred amid trade negotiations between the world's two largest economies, which have been locked in an escalating tariff and export control war since Trump returned to the Oval Office earlier this year. There was nothing but excitement about AI in the vast expo center in Shanghai's skyscraper-rich Pudong district, where crowds entered gates controlled by facial recognition. Inside, thousands of attendees listened to panels stacked with Chinese government officials, entrepreneurs and international researchers, or watched demonstrations on using AI to create video games, control robotic movements and respond in real time to conversations via smartglasses. Chinese giants like Huawei and Alibaba and newer Chinese tech darlings like Unitree Robotics were there. DeepSeek was not present, but its name was spoken everywhere. The Hangzhou-based upstart has been at the forefront of Beijing's attempt to push the government use of AI since it released a chatbot model in January, prompting a global craze and driving home China's rapid AI advances. DeepSeek has been put to work over the last six months on a wide variety of government tasks. Procurement documents show military hospitals in Shaanxi and Guangxi provinces specifically requesting DeepSeek to build online consultation and health record systems. Local government websites describe state organs using DeepSeek for things like diverting calls from the public and streamlining police work. DeepSeek helps 'quickly discover case clues and predict crime trends,' which 'greatly improves the accuracy and timeliness of crime fighting,' a city government in China's Inner Mongolia region explained in a February social media post. Anti-corruption investigations - long a priority for Chinese leader Xi Jinping - are another frequent DeepSeek application, in which models are deployed to comb through dry spreadsheets to find suspicious irregularities. In April, China's main anti-graft agency even included a book called 'Efficiently Using DeepSeek' on its official book recommendation list. China's new AI action plan underscores this push, declaring that the 'public sector should take the lead in deploying applications' by embedding AI in education, transportation and health care. It also emphasizes a mandate to use AI 'to empower the real economy' and praises open-source models - which are more easily shared - as an egalitarian method of AI development. Alfred Wu, an expert on China's public governance at the National University of Singapore, said Beijing has disseminated a 'top-down' directive to local governments to use AI. This is motivated, Wu said, by a desire to improve China's AI prowess amid a fierce rivalry with Washington by providing models access to vast stores of government data. But not everyone is convinced that China has the winning hand, even as it attempts to push AI application nationwide. For one, China's sluggish economy will impact the AI industry's ability to grow and access funding, said Singer, who was attending the conference. Beijing has struggled to manage persistent deflation and a property crisis, which has taken a toll on the finances of many families across the country. 'So much of China's AI policy is shaped by the state of the economy. The economy has been struggling for a few years now, and applications are one way of catalyzing much-needed growth,' he said. 'The venture capital ecosystem in AI in China has gone dry.' Others point out that local governments trumpeting their usage of DeepSeek is more about signaling than real technology uptake. Shen Yang, a professor at Tsinghua University's school of artificial intelligence, said DeepSeek is not being used at scale in anti-corruption work, for example, because the cases involve sensitive information and deploying new tools in these investigations requires long and complex approval processes. He also pointed out that AI is still a developing technology with lots of kinks. 'AI hallucinations still exist,' he said, using a term for the technology's generation of false or misleading information. 'If it's wrong, who takes responsibility?' These concerns, however, felt far away in the expo's humming hallways. At one booth, Carter Hou, the co-founder of Halliday, a smartglasses company, explained how the lenses project a tiny black screen at the top of a user's field of vision. The screen can provide translation, recordings and summaries of any conversation, and even deploy 'proactive AI,' which anticipates questions based on a user's interactions and provides information preemptively. 'For example, if you ask me a difficult question that is fact related,' Hou said, wearing the trendy black frames, 'all I need to do is look at it and use that information and pretend I'm a very knowledgeable person.' Asked about the event's geopolitical backdrop, Hou said he was eager to steer clear of diplomatic third rails. 'People talk a lot about the differences between the United States and China,' he said. 'But I try to stay out of it as much as possible, because all we want to do is just to build good products for our customers. That's what we think is most important.' Kiki Lei, a Shanghai resident who started an AI video company and attended the conference on Sunday, seemed to agree with this goal. She said that Chinese AI products are easier to use than U.S. products because companies here really 'know how to create new applications' and excel at catering to, and learning from, the large pool of Chinese technology users. Robots, perhaps the most obvious application of AI in the real world, were everywhere at the conference - on model factory floors and in convenience stores retrieving soda cans, shaking disbelieving kids' hands, or just roaming the packed halls. At the booth for ModelBest, another Beijing-based AI start-up, a young student from China's prestigious Tsinghua University, who was interning at the company, demonstrated how a robot could engage with its surroundings - and charm its human interlocutors. Looking directly at the student, the robot described his nondescript clothing. 'The outfit is both stylish and elegant,' the robot continued. 'You have a confident and friendly demeanor, which makes you very attractive.' - - - Pei-Lin Wu in Taiwan contributed to this report. --- Video Embed Code Video: Robots ruled at the World Artificial Intelligence Conference in Shanghai, where China displayed its latest tech and AI innovation. Washington Post China correspondent Katrina Northrop reported from the event on July 26.(c) 2025 , The Washington Post Embed code: Related Content Pets are being abandoned, surrendered amid Trump's immigration crackdown The Post exposed this farmer's struggle. Then the USDA called. Kamala Harris will not run for California governor, opening door for 2028 run Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
If You Bought Only 1 Share of Nvidia at Its IPO, Here's How Many Shares You'd Own Now
Key Points Nvidia's initial public offering (IPO) was on January 22, 1999. The company has executed six stock splits in its 26 years as a public company. Investors who held on to just one share from the IPO would have seen over $85,000 in gains. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has dominated stock market discussion over the past couple years, but it's far from a newcomer. The company was founded on April 5, 1993, and it began trading publicly after its initial public offering (IPO) on January 22, 1999. Had you bought one share of Nvidia stock at its IPO, you would currently have 480 shares, thanks to the six stock splits it has undergone in that time. Stock-Split Date Amount of the Stock Split June 2000 2-for-1 Sept. 2001 2-for-1 April 2006 2-for-1 Sept. 2007 3-for-2 July 2021 4-for-1 June 2024 10-for-1 Data source: Seeking Alpha. How much money would you have made in that time? Although Nvidia has been on the market for a quarter century, it hasn't always been the high-flying stock that investors have seen over the past few years. That said, had you bought one share of Nvidia at its IPO price of $12.00 per share and held on to it all this time, your investment would be worth $85,378 as of this writing. That works out to just under a 40% compound annual growth rate for your position. It's also worth noting that this rate of return doesn't include Nvidia's dividend, which it initiated in Nov. 2012. Anyone who reinvested their dividends would only have boosted their long-term returns. These are mind-boggling results, and Nvidia seems to have plenty left in the tank as it takes center stage in the growth of artificial intelligence. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. If You Bought Only 1 Share of Nvidia at Its IPO, Here's How Many Shares You'd Own Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Nektar Therapeutics (NASDAQ:NKTR) should be aware of the most powerful shareholder groups. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Nektar Therapeutics, beginning with the chart below. Check out our latest analysis for Nektar Therapeutics What Does The Institutional Ownership Tell Us About Nektar Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Nektar Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nektar Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Nektar Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Charles Schwab Investment Management, Inc. is the largest shareholder with 8.3% of shares outstanding. BVF Partners L.P. is the second largest shareholder owning 7.4% of common stock, and Millennium Management LLC holds about 5.4% of the company stock. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Nektar Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Nektar Therapeutics in their own names. It has a market capitalization of just US$397m, and the board has only US$4.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. General Public Ownership With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Nektar Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Nektar Therapeutics has 4 warning signs (and 3 which can't be ignored) we think you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
